Lung Cancer最新文献

{"title":"Validity and responsiveness of patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) among Italian lung cancer patients","authors":"Maria Lucia Iacovino ,&nbsp;Laura Arenare ,&nbsp;Alessandro Morabito ,&nbsp;Marcello Tiseo ,&nbsp;Andrea Antonuzzo ,&nbsp;Salvatore Pisconti ,&nbsp;Silvia Della Torre ,&nbsp;Elisa Anselmi ,&nbsp;Maura Rossi ,&nbsp;Filippo Giovanardi ,&nbsp;Roberto Bollina ,&nbsp;Francesca Zanelli ,&nbsp;Domenico Galetta ,&nbsp;Silvana Leo ,&nbsp;Domenico Bilancia ,&nbsp;Elisa Biscaldi ,&nbsp;Anna Manzo ,&nbsp;Roberta Camisa ,&nbsp;Agnese Montanino ,&nbsp;Vincenzo Sforza ,&nbsp;Francesco Perrone","doi":"10.1016/j.lungcan.2026.109312","DOIUrl":"10.1016/j.lungcan.2026.109312","url":null,"abstract":"<div><h3>Background</h3><div>Patient-reported symptom monitoring may improve the outcomes of cancer treatment. Knowledge of psychometric properties may drive the selection of optimal tools. Here we report the analysis of PRO-CTCAE in Italian lung cancer patients.</div></div><div><h3>Methods</h3><div>A PRO-CTCAE list (74 items, 44 symptoms) was administered to on-treatment patients at registration (visit 1) and after 2–6 weeks (visit 2). Convergent validity with EORTC LC-13 and Hospital Anxiety and Depression Scale (HADS) was assessed by Pearson correlation. Known-group validity and responsiveness were tested with ECOG performance status (PS 0 vs 1) and Patients’ Global Impression of Change (PGIC) scale as anchors, respectively.</div></div><div><h3>Results</h3><div>From September 2019 to November 2022, 186 patients filled PRO-CTCAE at visit 1 and 164 at visit 2. Median age (IQR) was 66.4 (60.9 – 73.1) years; 58.6% were male; 68.0% had PS 0. Convergent validity showed high correlation (r ≥ 0.50) of PRO-CTCAE hair loss (r = 0.78), dyspnoea (0.63), limb numbness (0.63), cough (0.58) and pain (0.51) with selected LC-13 anchors. PRO-CTCAE anxiety, depression and sadness highly correlated with HADS. For known-group validity, small to medium correlations were found for oral, cutaneous and respiratory toxicity, fatigue, appetite loss, insomnia and depression, that were worse for PS 1; limb swelling and pain were worse in PS 0. Responsiveness analysis at visit 2 found some PRO-CTCAE score changes consistently and directly correlated with impression of change measured with PGIC.</div></div><div><h3>Conclusions</h3><div>These results support the use of selected PRO-CTCAE items for lung cancer patients as a reliable tool for detection of treatment related toxicities.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"214 ","pages":"Article 109312"},"PeriodicalIF":4.4,"publicationDate":"2026-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146147566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep exploration of sotorasib-related hepatobiliary AEs: Based on FDA Adverse Event reporting system","authors":"Xinmei Pan ,&nbsp;Lin Zhang ,&nbsp;Linli Xie,&nbsp;Xiaohong Li,&nbsp;Ying Li,&nbsp;Qian Wang,&nbsp;Jing Hu","doi":"10.1016/j.lungcan.2026.109311","DOIUrl":"10.1016/j.lungcan.2026.109311","url":null,"abstract":"<div><h3>Objectives</h3><div>This study focused on the exploration of sotorasib-related hepatobiliary adverse events (AEs) through the US Food and Drug Administration Adverse Event Reporting System (FAERS) database, to provide reference for safe clinical use.</div></div><div><h3>Materials and methods</h3><div>We extracted sotorasib AEs report data from FAERS database from May 28, 2021 to September 30, 2024. Four algorithms were used for disproportionality analysis to comprehensively identify AEs signals related to sotorasib, including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi item gamma Poisson shrinker (MGPS). We focused on analyzing and evaluating the signals of hepatobiliary AEs and described their characteristics and risk factors.</div></div><div><h3>Results</h3><div>We collected 2383 AEs with sotorasib as the main suspected drug. Among them, 291 cases were related to hepatobiliary AEs, involving 36 PTs, of which 15 PTs had positive signals. Eleven PTs in the positive signals were identified not listed in the drug instructions, among which hepatic function abnormal, cholestasis, and cholestatic liver injury had strong signals. There was still a correlation between sotorasib and hepatobiliary AEs after analyzed by gender, age, reporter type, and serious reports, but the atlas was different in the hierarchical scheme. Hepatotoxicity and drug-induced liver injury were classified as moderate clinical priority and should be given priority in clinical practice.</div></div><div><h3>Conclusion</h3><div>This study obtained the real hepatobiliary toxicity spectrum, characteristics, and influencing factors of sotorasib through FAERS data mining, which provides valuable insights for healthcare professionals to effectively manage the risk of sotorasib-related hepatobiliary AEs in clinical practice.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"214 ","pages":"Article 109311"},"PeriodicalIF":4.4,"publicationDate":"2026-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146147571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small cell lung cancer","authors":"Kazumasa Akagi ,&nbsp;Hirokazu Taniguchi ,&nbsp;Minoru Fukuda ,&nbsp;Takuya Yamazaki ,&nbsp;Daisuke Takao ,&nbsp;Ryuta Tagawa ,&nbsp;Fumiko Hayashi ,&nbsp;Ryosuke Ogata ,&nbsp;Sawana Ono ,&nbsp;Hiromi Tomono ,&nbsp;Takayuki Suyama ,&nbsp;Noritaka Honda ,&nbsp;Yasuhiro Umeyama ,&nbsp;Yosuke Dotsu ,&nbsp;Midori Matsuo ,&nbsp;Hiroshi Gyotoku ,&nbsp;Hiroaki Senju ,&nbsp;Shinnosuke Takemoto ,&nbsp;Hiroshi Soda ,&nbsp;Takashi Mizowaki ,&nbsp;Hiroshi Mukae","doi":"10.1016/j.lungcan.2026.109310","DOIUrl":"10.1016/j.lungcan.2026.109310","url":null,"abstract":"<div><h3>Background</h3><div>Etoposide plus cisplatin (EP) with concurrent accelerated hyperfractionated thoracic radiotherapy (AHTRT) remains the standard treatment for unresectable limited-stage (LS) small cell lung cancer (SCLC)) for over two decades. Our previous study demonstrated that amrubicin plus cisplatin (AP) with once-daily thoracic radiotherapy (50 Gy per 25 fractions) for LS-SCLC prolonged overall survival (OS) to 39.5 months with manageable toxicities. To enhance therapeutic efficacy, this study aimed to assess the feasibility of AP combined with AHTRT for LS-SCLC.</div></div><div><h3>Methods</h3><div>Treatment-naïve patients aged 20–75 years with LS-SCLC, performance status 0–1, and adequate organ function were enrolled. Chemotherapy consisted of cisplatin 60 mg/m²/day (day 1) and amrubicin (days 1–3), administered concurrently with AHTRT (1.5 Gy/time, twice daily, 45 Gy in total). The initial amrubicin dose was set to 25 mg/m² and increased to 35 mg/m² from the second cycle.</div></div><div><h3>Results</h3><div>Nine patients were enrolled in this study. Dose-limiting toxicities included Grade 3 febrile neutropenia and Grade 3 hypokalemia. The recommended and maximum tolerated dose of amrubicin was 25 mg/m². The overall response rate was 100%, with both median progression-free survival and OS not reached. The 5-year OS rate was 64.8%.</div></div><div><h3>Conclusion</h3><div>AP combined with AHTRT from the first chemotherapy cycle was well tolerated at the recommended amrubicin dose of 25 mg/m². This regimen demonstrated promising efficacy and may represent a potential therapeutic option for LS-SCLC.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"214 ","pages":"Article 109310"},"PeriodicalIF":4.4,"publicationDate":"2026-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146147564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Participation in lung cancer biospecimen studies: an analysis of the ECOG-ACRIN phase 3 E1505 and E5508 clinical trials","authors":"Yating Wang ,&nbsp;Zhuoxin Sun ,&nbsp;Arthi Sridhar ,&nbsp;Suresh S. Ramalingam ,&nbsp;Heather A. Wakelee ,&nbsp;David E. Gerber","doi":"10.1016/j.lungcan.2026.109304","DOIUrl":"10.1016/j.lungcan.2026.109304","url":null,"abstract":"<div><h3>Background</h3><div>Biospecimen analyses may provide important insights into patient selection and pharmacodynamic effects. To provide generalizable findings, such studies must enroll adequate and diverse populations.</div></div><div><h3>Methods</h3><div>We analyzed patient and institutional characteristics according to agreement to participate in optional, embedded biospecimen studies among patients enrolled in the E1505 and E5508 phase 3 lung cancer therapeutic trials. Differences were compared using Wilcoxon rank sum test, Pearson’s Chi-squared test, and logistic regression.</div></div><div><h3>Results</h3><div>Overall, 3,017 patients were enrolled in the two trials. Mean age was 63 years, 49% were female, and 83% were non-Hispanic white. Among these individuals, 2,692 (89%) agreed to participate in at least one biospecimen study, and 2,577 (85%) agreed to studies requiring future biospecimen collection. In multivariable logistic regression, compared to non-Hispanic white patients, other patients were less likely to agree to participate: OR 0.59 (95% CI, 0.45–0.79; <em>P</em> &lt; 0.001) for any biospecimen study; OR 0.62 (95% CI, 0.48–0.80; <em>P</em> &lt; 0.001) for studies requiring future biospecimen collection. Women and patients treated outside main academic institutions (e.g., affiliates, community sites) were also less likely to participate.</div></div><div><h3>Conclusions</h3><div>Among patients enrolled in lung cancer clinical trials, women, racial and ethnic minorities, and patients treated outside major academic centers are less likely to participate in optional biospecimen studies. Because some of these populations may already be under-represented in trial populations, this pattern may exacerbate disparities in translational and clinical research.</div><div><strong>Trial registration:</strong> NCT00324805, NCT01107626.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"214 ","pages":"Article 109304"},"PeriodicalIF":4.4,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146147569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of first-line lenvatinib in patients with advanced or recurrent thymic carcinoma in the real-world setting","authors":"Ryosuke Tsugitomi ,&nbsp;Kento Takagi ,&nbsp;Go Saito ,&nbsp;Motoko Tachihara ,&nbsp;Hironori Ashinuma ,&nbsp;Takehito Shukuya ,&nbsp;Shinnosuke Takemoto ,&nbsp;Shinya Sakata ,&nbsp;Atsuto Mouri ,&nbsp;Hideki Miwa ,&nbsp;Yosuke Tamura ,&nbsp;Takaaki Tokito ,&nbsp;Yoko Tsukita ,&nbsp;Yoshihito Kogure ,&nbsp;Takeshi Masuda ,&nbsp;Hiroshi Tanaka ,&nbsp;Sousuke Kubo ,&nbsp;Takaaki Sasaki ,&nbsp;Tomohiro Oba ,&nbsp;Nobuaki Mamesaya ,&nbsp;Takuji Suzuki","doi":"10.1016/j.lungcan.2026.109309","DOIUrl":"10.1016/j.lungcan.2026.109309","url":null,"abstract":"<div><h3>Background</h3><div>Thymic carcinoma is a rare thoracic malignancy with limited first-line treatment options. Lenvatinib has shown efficacy and tolerability in previously treated patients, but its role in chemotherapy-naive patients is unclear.</div></div><div><h3>Methods</h3><div>We conducted a retrospective, multicentre observational study across 31 Japanese institutions. Patients with advanced or recurrent thymic carcinoma who received lenvatinib between 23 March 2021 and 31 October 2022 were included. Data cut-off was 13 November 2024. Outcomes for chemotherapy-naive patients included objective response rate (ORR), progression-free survival (PFS), disease control rate (DCR), time to treatment failure (TTF), overall survival (OS), and adverse events (AEs). Subgroup analyses were stratified by age.</div></div><div><h3>Results</h3><div>Of 107 patients, 20 received lenvatinib as first-line therapy. Median observation was 23.6 months (interquartile range, 12.5–27.1). ORR was 50% (90% confidence interval [CI], 27.2–72.8%), and DCR 85% (95% CI, 62.1–96.8%). Median PFS, TTF, and OS were 10.9 months (95% CI, 5.6–17.1), 8.9 months (95% CI, 5.3–17.8), and 25.0 months (95% CI, 21.2–not reached). AEs occurred in 95% (Grade ≥ 3 in 60%); dose reductions and discontinuations occurred in 85% and 25%. Safety was consistent with prior reports. Older patients showed higher rates of Grade ≥ 3 AEs and discontinuation.</div></div><div><h3>Conclusions</h3><div>In this real-world cohort, first-line lenvatinib demonstrated favourable efficacy and manageable safety, supporting its use in advanced or recurrent thymic carcinoma.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"214 ","pages":"Article 109309"},"PeriodicalIF":4.4,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146147565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Letter to the Editor entitled “Methodological considerations in assessing the clinical impact of TP53 classifications in advanced NSCLC”","authors":"Deborah Di-Xin Zhou,&nbsp;Chee Khoon Lee","doi":"10.1016/j.lungcan.2026.109303","DOIUrl":"10.1016/j.lungcan.2026.109303","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"214 ","pages":"Article 109303"},"PeriodicalIF":4.4,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146147570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HDAC1-modified lamin A/C drives nuclear deformation in RB1-deficient lung adenocarcinoma","authors":"Hongxia Li ,&nbsp;Yu Chen ,&nbsp;Lihong Wei ,&nbsp;Peng Wu ,&nbsp;Fei Fang ,&nbsp;Fengru Li ,&nbsp;Bixia Liu ,&nbsp;Shuhua Li ,&nbsp;Qiong He ,&nbsp;Jianwen Zhou ,&nbsp;Kejing Tang ,&nbsp;Zunfu Ke","doi":"10.1016/j.lungcan.2026.109301","DOIUrl":"10.1016/j.lungcan.2026.109301","url":null,"abstract":"<div><h3>Background</h3><div>Lineage transformation from lung adenocarcinoma (LUAD) to small cell lung cancer (SCLC) represents a rare yet well-documented off-target mechanism associated with acquired resistance to tyrosine kinase inhibitors (TKIs). However, the relationship between this transformation and morphological changes remains inadequately understood. This study seeks to elucidate the molecular mechanisms by which RB1 depletion facilitates lineage transformation, with a particular emphasis on its role in morphological alterations.</div></div><div><h3>Methods</h3><div>Integrated molecular, morphological, and structural analyses were conducted in RB1-deficient LUAD models in vitro and in vivo. Functional perturbation and pharmacological inhibition of RB1-associated regulators were further performed to delineate the mechanism of the RB1/E2F1/HDAC1 axis.</div></div><div><h3>Results</h3><div>Patients with LUAD exhibiting low expression levels of TP53 and RB1 exhibited enhanced tumor invasion characteristics and a poor clinical prognosis. Our findings demonstrated that RB1 depletion induced epithelial-mesenchymal transition (EMT) characteristics in LUAD cells, as evidenced by spindle-shaped morphology, increased vimentin expression, and decreased E-cadherin expression. Furthermore, RB1 loss is responsible for nuclear abnormalities, including irregular distribution of nuclear hallmarks such as lamin A/C and emerin, which contribute to tumor aggressiveness. Through the downregulation of individual components of the RB1/E2F1/HDAC1 complex, we identified HDAC1 as a key regulatory factor influencing lamin A/C modification and nuclear deformation. Pharmacological inhibition of HDAC1 derivatives ameliorates the nuclear abnormalities observed in RB1-depleted lung cancer cells, suggesting a potential therapeutic strategy. Mechanistically, the loss of acetylated lamin A/C leads to its degradation and granular distribution, resulting in compromised nuclear mechanostability and defective cytoskeletal dynamics, which may elucidate the observed EMT.</div></div><div><h3>Conclusions</h3><div>Collectively, our findings suggested that the downregulation of RB1 significantly influences the morphology of LUAD by facilitating EMT and nuclear abnormalities through HDAC1-mediated deacetylation of lamin A/C. Future research should prioritize the development of targeted therapies aimed at restoring RB1 function or inhibiting HDAC1 to mitigate cancer progression, thereby enhancing patient stratification and treatment strategies in TKI-resistant LUAD.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"214 ","pages":"Article 109301"},"PeriodicalIF":4.4,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146147572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic landscape of stage 0–IA lung adenocarcinoma identified by on-site reflex targeted NGS","authors":"Marius Ilié ,&nbsp;Simon Heeke ,&nbsp;Guylène Rignol ,&nbsp;Radu Pirlog ,&nbsp;Samantha Goffinet ,&nbsp;Elodie Long-Mira ,&nbsp;Sandra Lassalle ,&nbsp;Virginie Lespinet-Fabre ,&nbsp;Olivier Bordone ,&nbsp;Virginie Tanga ,&nbsp;Caroline Lacoux ,&nbsp;Christelle Bonnetaud ,&nbsp;Jonathan Benzaquen ,&nbsp;Jacques Boutros ,&nbsp;Charlotte Cohen ,&nbsp;Abel Gomez-Caro ,&nbsp;Charles Hugo Marquette ,&nbsp;Jean-Philippe Berthet ,&nbsp;Véronique Hofman ,&nbsp;Paul Hofman","doi":"10.1016/j.lungcan.2026.108943","DOIUrl":"10.1016/j.lungcan.2026.108943","url":null,"abstract":"<div><h3>Introduction</h3><div>Early molecular profiling in non-squamous non-small cell lung carcinoma (NSCLC), particularly lung adenocarcinoma (LUAD), is critical for guiding individualized treatment strategies. Limited data exist on the genomic landscape of Stage 0–IA LUAD. This study assessed the feasibility and clinical relevance of reflex targeted next-generation sequencing (NGS) performed on-site at diagnosis in resected early-stage LUAD.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed 239 consecutive Stage 0–IA LUAD cases diagnosed between 2022 and 2024 at a single institution. Ultra-fast reflex DNA- and RNA-based NGS was performed on resected specimens using a 50-gene targeted panel. Alterations were classified according to the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT). Associations between genomic alterations, histologic subtypes, and tumor grades were evaluated.</div></div><div><h3>Results</h3><div>Stage IA1 was the most frequent diagnosis (46%). High-quality sequencing data were obtained in all cases, with a median turnaround time of 102 h. At least one genomic alteration was detected in 80% of tumors. <em>KRAS</em> mutations were most frequent (35.8%), including <em>KRAS</em> G12C in 16%. <em>EGFR</em> mutations were present in 27.2%, primarily classical sensitizing alterations. Other actionable findings included <em>ALK</em> fusions (3.3%), <em>RET</em> rearrangements (1.2%), <em>MET</em> exon 14 skipping (2.4%), <em>HER2</em> mutations (3.7%), and <em>BRAF</em> V600E (0.8%). ESCAT Level I alterations were found in 34% of tumors; 20% of these co-occurred with <em>TP53</em> mutations. Significant associations were observed between genomic alterations, histologic subtypes, and tumor grades.</div></div><div><h3>Conclusions</h3><div>Reflex NGS at diagnosis in resected Stage 0–IA LUAD is feasible, rapid, and reveals a high rate of actionable alterations, which may support its integration in the future into early-stage diagnostic workflows.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"213 ","pages":"Article 108943"},"PeriodicalIF":4.4,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146079604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Radiotherapy outcomes in patients with interstitial lung disease and interstitial lung abnormalities: Adverse events and survival from a UK tertiary centre\" [Lung Cancer 211 (2026) 108873.","authors":"Sarah Bowen Jones, Gerard Gurumurthy, Conal Hayton, Ahmad Lodhi, Aqeel Umar, Corinne Faivre-Finn","doi":"10.1016/j.lungcan.2026.108942","DOIUrl":"https://doi.org/10.1016/j.lungcan.2026.108942","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":" ","pages":"108942"},"PeriodicalIF":4.4,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146092913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune-inflammatory predictors of early and brain recurrence in young patients with resected non-small cell lung cancer","authors":"Debora Brascia ,&nbsp;Giuseppe Mangiameli ,&nbsp;Maria Teresa Congedo ,&nbsp;Maria Giovanna Mastromarino ,&nbsp;Chiara Catelli ,&nbsp;Marco Schiavon ,&nbsp;Veronica Giudici ,&nbsp;Alessia Senatore ,&nbsp;Alessandro Bonis ,&nbsp;Marco Lucchi ,&nbsp;Luca Luzzi ,&nbsp;Stefano Magaritora ,&nbsp;Federico Rea ,&nbsp;Giuseppe Marulli","doi":"10.1016/j.lungcan.2026.108946","DOIUrl":"10.1016/j.lungcan.2026.108946","url":null,"abstract":"<div><h3>Objectives</h3><div>Non–small-cell lung cancer (NSCLC) diagnosed before the age of 50 is uncommon and remains poorly characterized from a prognostic perspective. This study aimed to identify clinical, pathological, and inflammatory–immune predictors of recurrence, early recurrence, and brain metastasis after curative resection in young patients.</div></div><div><h3>Methods</h3><div>This multicenter retrospective study included 224 consecutive patients aged &lt;50 years who underwent anatomical lung resection between 2015 and 2024 at five Italian centers. Recurrence-free survival (RFS) was analyzed using Fine–Gray competing-risk regression and overall survival (OS) using Cox proportional hazards models. Early recurrence was defined as occurring within 12 months after surgery. The prognostic value of preoperative neutrophil-to-lymphocyte ratio (NLR), PD-L1 expression, and their combined phenotypes was explored. An exploratory ROC-derived NLR cut-off of 2.35 was used for stratification.</div></div><div><h3>Results</h3><div>During follow-up, 65 patients (29.0%) experienced recurrence, with brain metastases representing the most frequent distant site (10.3% overall). Early recurrence occurred in 11.6% of patients. On multivariable analysis, higher NLR independently predicted recurrence (sHR 1.37, 95% CI 1.09–1.73), mortality (HR 1.82, 95% CI 1.27–2.61), and early recurrence (OR 3.61, 95% CI 1.07–12.21). PD-L1 expression alone was not prognostic; however, when combined with NLR, it identified inflammatory–immunologic phenotypes with different risks of brain metastasis among patients who recurred (p = 0.051).</div></div><div><h3>Conclusions</h3><div>Young-onset NSCLC is characterized by a high burden of early and distant recurrence, particularly involving the brain. Preoperative NLR is a robust predictor of recurrence, early relapse, and mortality. Combined NLR–PD-L1 phenotypes identify a subgroup at increased risk of neurotropic relapse.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"213 ","pages":"Article 108946"},"PeriodicalIF":4.4,"publicationDate":"2026-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146078924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}